Compare PANL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.2M | 535.5M |
| IPO Year | 2015 | 2019 |
| Metric | PANL | FULC |
|---|---|---|
| Price | $7.17 | $7.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $16.38 |
| AVG Volume (30 Days) | 437.7K | ★ 871.0K |
| Earning Date | 05-11-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $385,088,209.00 | N/A |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.94 | $3.45 |
| 52 Week High | $9.39 | $15.74 |
| Indicator | PANL | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 50.67 |
| Support Level | $6.59 | $7.40 |
| Resistance Level | $7.35 | $8.20 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 11.31 | 54.08 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.